We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Jan 2016

Sale of a Mammalian Cell Culture Biologics API Manufacturing Facility

Baxalta Brooklyn Park

PharmaBioSource Realty provided real estate services to Baxalta on the sale of its 215,000 SF Brooklyn Park, Minnesota mammalian cell culture biologics drug substance facility to Takeda.

  • Service: Real Estate
  • Sector: Biotechnology
  • Sub-sector: Mammalian Cell Culture Drug Substance
  • Engagement Type: Sell Side

PharmaBioSource Realty provided exclusive life sciences real estate services to divest Baxalta’s mammalian cell culture drug substance facility near Minneapolis. The facility was acquired by Takeda to manufacture Entyvio® and other biologic products. The facility houses 2 x 20,000L and 2 x 1,000L bioreactors with associated downstream suites, QC laboratories, offices and GMP warehouse space.

PharmaBioSource’s services included a benchmark valuation, buyer target identification, creation of the confidential information memorandum (CIM), data room development and due diligence support.  Nine competing offers were received for the facility.

Press Release

Transactions

View All Transactions